101. Comparison of HiDAC Versus FLAG‐IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High‐Risk Myelodysplastic Syndrome.
- Author
-
Tang, Man Wai, Van der Tuin, Deborah, Aydin, Mesire, Heijmans, Jarom, Van de Loosdrecht, Arjan A., Meijer, Ellen, Rutten, Caroline E., Wondergem, Mariëlle, Janssen, Jeroen J. W. M., Donker, Marjolein L., Hazenberg, Mette D., Zweegman, Sonja, Biemond, Bart J., De Leeuw, David C., and Nur, Erfan
- Subjects
- *
ACUTE myeloid leukemia , *MYELODYSPLASTIC syndromes , *SURVIVAL rate , *PROGNOSIS , *CYTARABINE - Abstract
ABSTRACT Background Methods Results Conclusion Relapsed acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) are associated with a poor prognosis. It is unknown which re‐induction therapy provides the highest chance of durable remission. Commonly used therapies are high dose cytarabine (HiDAC) and triple therapy consisting of fludarabine, cytarabine, and idarubicin combined with granulocyte colony‐stimulating factor (FLAG‐IDA).Two patient cohorts with relapsed AML or HR‐MDS treated with HiDAC or FLAG‐IDA between October 2015 and December 2021 in two academic hospitals in the Netherlands were retrospectively analyzed.Patients were treated with either HiDAC (n=22) or FLAG‐IDA (n=25). Rates of CR (71% vs. 74%, P=0.85), 1‐year OS (47% vs. 51%, P=0.99) and EFS (38% vs. 35%, P=0.71) were comparable between HiDAC and FLAG‐IDA. Durations of neutropenia (median 24 days (IQR 20‐26) vs. 30 days (IQR 22‐39), P=0.014) and thrombocytopenia (22 days (IQR 17‐26) vs. 36 days (IQR 26‐53)) were significantly shorter in the HiDAC group than in the FLAG‐IDA group.While remission rates and survival outcomes were similar, FLAG‐IDA was associated with longer periods of myelosuppression and transfusion dependency compared to HiDAC in these two cohorts. HiDAC can be considered as a salvage chemotherapyfor relapsed AML/HR‐MDS based on our study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF